Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.40 |
| ▸ | MMP3 | P08254 | 12/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437433 | 0.85 | MMP2 (0.41) | MMP2MMP3L3MBTL1 | |
| SCHEMBL6433527 | 0.83 | MMP2 (0.47) | MMP2MMP3PRMT5EGLN1L3MBTL1 | |
| SCHEMBL6437646 | 0.71 | MMP2 (0.48) | MMP2MMP3L3MBTL1PTGDR | |
| SCHEMBL6433591 | 0.71 | MMP2 (0.55) | MMP2MMP3GAAPTGDR | |
| SCHEMBL6590027 | 0.70 | MMP2 (0.61) | MMP2MMP3 | |
| SCHEMBL6590755 | 0.70 | MMP2 (0.52) | MMP2MMP3ALDH1A1GAA | |
| SCHEMBL6586866 | 0.69 | MMP2 (0.54) | MMP2MMP3 | |
| SCHEMBL6586244 | 0.69 | MMP2 (0.49) | MMP2MMP3EGLN1L3MBTL1 | |
| SCHEMBL6587154 | 0.69 | MMP2 (0.52) | MMP2MMP3L3MBTL1ALDH1A1GAA | |
| SCHEMBL6436317 | 0.69 | PTGER1 (0.37) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1181017-B1 | METALLOPROTEASE INHIBITORS | PFIZER LTD (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-6511993-B1 | Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes | PFIZER INC. | 2003-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | MMP2 19/4885MMP3 28/4885PRMT5 4399/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | MMP2 19/4885MMP3 28/4885PRMT5 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.